Another Early-Stage VC Win: Pliant Raises $45m For Fibrosis Startup
This article was originally published in Scrip
As venture capital investment in biotechnology skyrockets, the amount of money that companies can raise in first-time financings also is soaring to new heights, and the fibrosis-focused startup Pliant Therapeutics Inc. with its $45m Series A round is no exception to the new biotech VC rule.
You may also be interested in...
Private Company Edition: Immunocore’s $130m round kicked off a series of $100m-plus venture capital deals, including financings for Xilio, Akouos and Pliant. Also, VC investment in cell and gene therapies surged in 2019 and MPM launched two funds with $126 for early cancer research.
With biopharma venture capital investment of $9.67bn during the first half, 2018's total is on track to beat 2017 in the third quarter. IPOs, one of the factors fueling VC investment, continue to boom with five more drug developers slated to go public this week.
Allergan will pay a huge premium – up to $1.7bn in a milestone-heavy deal – for Tobira and $50m up front for the preclinical startup Akarna to expand its gastrointestinal franchise into the potentially lucrative NASH market.